Rome Therapeutics raises $77m for junk DNA-targeting drugs
pharmaphorum
SEPTEMBER 14, 2021
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein.
Let's personalize your content